FDMT — 4D Molecular Therapeutics Share News
0.000.00%
Last trade - 00:00- $710.99m
- $369.25m
- $85.21m
4D Molecular buys rights to Fortress Biotech's gene therapy, shares slip
Brief: Aevitas Therapeutics, A Fortress Biotech Subsidiary, Announces Asset Purchase Agreement With 4D Molecular Therapeutics For World-Wide Rights To Aevitas’ Short-Form Human Complement Factor H
Brief: 4Dmt Acquires Complement Pathway Inhibitor Payload For 4D-175 Product Candidate For Geographic Atrophy
Brief: 4Dmt To Present Interim Data From Phase 1/2 Prism Clinical Trial For Wet AMD At Arvo 2023
Brief: 4D Molecular Therapeutics Reports FY 2022 Financial Results And Operational Highlights
Brief: 4DMT To Present Interim Clinical Data From Inglaxa Phase 1/2 Trials Of 4D-310 For Fabry Disease Cardiomyopathy At 19Th Annual Worldsymposium
U.S. RESEARCH ROUNDUP-Booking Holdings, Dow, Hub Group
Brief: 4D Molecular Therapeutics Announces FDA Clearance Of Ind Application For 4D-150 Genetic Medicine For The Treatment Of Diabetic Macular Edema
Brief: 4D Molecular Therapeutics Announces Updates On Clinical Pipeline And Additional Preclinical Programs
U.S. STOCKS ON THE MOVE-Grindr, Utilities, StoneCo, Carvana
H.C. Wainwright starts coverage of 4D Molecular with 'buy'
U.S. RESEARCH ROUNDUP-Calithera Biosciences, Haynes International, Lumos Pharma
Brief: 4D Molecular Therapeutics Announces Interim Clinical Data From On-Going Phase 1/2 Clinical Trial Of Intravitreal 4D-150 For Wet Age-Related Macular Degeneration (Wet AMD)
4D Molecular rises on positive interim data for eye injection
Brief: 4D Molecular Therapeutics Interim Clinical Data From The On-Going Phase 1/2 Clinical Trial Of 4D-150 For Wet AMD To Be Released Monday, Nov. 14
U.S. RESEARCH ROUNDUP-Amyris, HanesBrands, Roblox
Brief: 4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results
4D Molecular Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
4D Molecular Therapeutics Inc expected to post a loss of 91 cents a share - Earnings Preview